EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Restricted cubic spline analysis of treatment duration before tocilizumab withdrawal and relapse risk in rheumatoid arthritis

Houhui Jiang, Yuxin Yan, Sheng Zhao, Rui Wu iD

Therapeutic Advances in Musculoskeletal Disease · 2026-07 · 18

DOI: 10.1177/1759720x261464266 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Musculoskeletal Disease, online erschienen am 04.07.2026. Verfasst von Houhui Jiang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tocilizumab (TCZ), an interleukin-6 receptor inhibitor, is effective for moderate to severe rheumatoid arthritis (RA). However, maintaining remission after TCZ withdrawal remains challenging, and the treatment duration required before discontinuation to minimize relapse risk is unclear.

Objectives

To identify a TCZ treatment-duration threshold before withdrawal that is associated with a lower risk of relapse in patients with RA.

Design

This was a retrospective study including 97 patients with RA who discontinued intravenous TCZ after stable disease control.

Methods

We retrospectively analyzed 97 RA patients who achieved remission or low disease activity prior to TCZ withdrawal. The primary outcome was relapse within 12 months post-discontinuation. Cox proportional hazards regression identified independent predictors, while restricted cubic spline (RCS) modeling assessed non-linear associations between treatment duration and relapse risk. A simplified risk stratification tool was developed and internally validated using bootstrap resampling.

Results

Among 97 patients with RA who discontinued TCZ after stable disease control, most were biologic-naïve (98.9%), the mean disease duration was 72.9 ± 52.7 months, and concomitant methotrexate and hydroxychloroquine were used in 73.2% and 47.4% of patients, respectively. During the 12-month follow-up, 54 patients (55.7%) relapsed. TCZ treatment duration was an independent protective factor (adjusted HR = 0.892 per month, p = 0.002), whereas anti-citrullinated protein antibody (ACPA) positivity was associated with increased relapse risk (adjusted HR = 2.122, p = 0.031). RCS analysis demonstrated an L-shaped non-linear relationship, identifying an empirically derived duration threshold at approximately 200 days associated with lower relapse risk. A simplified score assigning 1 point each for ACPA positivity and TCZ duration < 200 days stratified patients into low- (0 points), intermediate- (1 point), and high-risk (2 points) groups, with relapse rates of 27.3%, 53.8%, and 91.7%, respectively; the model showed acceptable discrimination (AUC = 0.76).

Conclusion

Longer TCZ treatment duration and ACPA negativity were associated with a lower risk of relapse after TCZ withdrawal. An approximately 200-day treatment duration may serve as a clinically informative threshold for risk-stratified withdrawal decisions in routine practice, although disease control after withdrawal should be interpreted in the context of ongoing background therapy rather than confirmed drug-free remission.

Schlagwörter

Stichwörter der Autor:innen

relapserheumatoid arthritistocilizumabtreatment duration

Autor:innen und Institutionen

  • Department of Rheumatology and Immunology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
  • Department of Rheumatology and Immunology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17, Yongwaizheng Street, Donghu District, Nanchang, Jiangxi 330006, China.

ORCID-Profile: Rui Wu

Zitieren

APA

Jiang, H., Yan, Y., Zhao, S., & Wu, R. (2026). Restricted cubic spline analysis of treatment duration before tocilizumab withdrawal and relapse risk in rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease, 18. https://doi.org/10.1177/1759720x261464266

Vancouver

Jiang H, Yan Y, Zhao S, Wu R. Restricted cubic spline analysis of treatment duration before tocilizumab withdrawal and relapse risk in rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease. 2026;18. doi:10.1177/1759720x261464266

BibTeX
@article{Jiang2026,
  author = {Jiang, Houhui and Yan, Yuxin and Zhao, Sheng and Wu, Rui},
  title = {Restricted cubic spline analysis of treatment duration before tocilizumab withdrawal and relapse risk in rheumatoid arthritis},
  journal = {Therapeutic Advances in Musculoskeletal Disease},
  year = {2026},
  volume = {18},
  doi = {10.1177/1759720x261464266}
}
Kostenlos starten →